Industry reports
Editor highlights

Search inside this page

Publishers

  • All
    • Global Data

All regions

Free Market Research Guides to Download

Pathology Analysis & Statistics, April 2014

You might be interested in: cancer, breast cancer, prostate cancer, more »

» Purchase Premium Reports

1-30 of about 2 000 reports
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • January 2014
  • by Global Data

PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked ...

  • Industries : Pathology
  • Countries : World
PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • February 2014
  • by Global Data

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, United Kingdom, Europe
OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017

  • $ 5 995
  • Industry report
  • March 2014
  • by Global Data

OpportunityAnalyzer: Pancreatic Cancer - Opportunity Analysis and Forecasts to 2017 Summary With five-year survival only approximately 5%, pancreatic cancer is characterized as a disease with some of the ...

  • Industries : Pathology
  • Countries : United States, World, Europe, Spain, Italy, France, Germany
PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • February 2014
  • by Global Data

PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...

  • Industries : Pathology
  • Countries : Japan
PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • February 2014
  • by Global Data

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : United States
EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023

EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • April 2014
  • by Global Data

EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023 Summary Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, United States, United Kingdom
EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022

  • $ 3 995
  • Industry report
  • March 2014
  • by Global Data

EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2022 Summary Ankylosing spondylitis is a systemic, chronic, and progressive inflammatory arthritis in the family of seronegativespondyloarthritis, ...

  • Industries : Pathology
  • Countries : World, United States, Japan, Europe, Sweden, Spain, Italy, France, Germany, Finland
EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • February 2014
  • by Global Data

EpiCast Report: Major Depressive Disorder - Epidemiology Forecast to 2023 Summary Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as one of ...

  • Industries : Pathology
  • Countries : World, Australia, Spain, Italy, France, Germany, Japan
EpiCast Report: Migraine - Epidemiology Forecast to 2023

EpiCast Report: Migraine - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • February 2014
  • by Global Data

EpiCast Report: Migraine - Epidemiology Forecast to 2023 Summary Migraine is typically characterized by recurring headaches, throbbing pain on one side of the head along with one or more of the following ...

  • Industries : Pathology
  • Countries : World, Japan, United States, Spain, Italy, France, Germany
Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, Japan, World, Europe, United States, United Kingdom
Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Geodon (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States
Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States, United Kingdom
Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Japan, World, United States
Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Invega (Schizophrenia) - Forecast and Market Analysis to 2022

Invega (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Invega (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022

Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Cimzia (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022

Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Entyvio (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Humira (Crohn's Disease) - Forecast and Market Analysis to 2022

Humira (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Humira (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Prochymal (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will ...

  • Industries : Pathology
  • Countries : Canada, World, United States, India, China
Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022

Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Remicade (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology

» View Public Reports

About 12 000 reports

The Australian Pharmaceutical Business Brief

  • Industry report
  • April 2014
  • 8 pages
  • by Corporation

... To compare the expenditure of other chronic diseases, particularly chronic diseases that share many of the same risk factors such as ckd [14]. As a result, this investigation will determine and compare ...

U.s. Diabete Sector

April 2014

» Read our Company Profiles

32 Companies

GlaxoSmithKline P.L.C.

United States

Celgene Corp.

United States

Eli Lilly and Co.

United States

Pfizer Inc.

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.